Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...